| eS-Expert-ID |
Expertise |
Experience |
Affiliation |
| eSE001 |
Proteomics, Mass Spectrometry, Systems Biology |
Biotech Advisor |
ETH Zürich |
| eSE002 |
Glycosylation, Glycomics |
Glycovaxyn, Dualsystems |
ETH Zürich |
| eSE003 |
Signaling, Oncology |
Genentech, The Genetics Company,
Biotech Advisor |
EPFL |
| eSE004 |
Neurodegeneration, Prion disease |
Chiron, Biotech Advisors |
University of Zürich |
| esE005 |
Signaling, Oncology |
The Genetics Company |
University of Zürich |
| eSE006 |
Clinical Oncology |
President of Swiss Cancer League |
Hospital St. Gallen |
| eSE007 |
Signaling, Cancer, Metabolic Disease |
The Genetics Company, Biotech Advisor |
ETH Zürich |
| eSE008 |
Apoptosis, Oncology, Neurobiology |
Devgen, Biotech Advisor |
University of Zürich |
| eSE009 |
Signaling, Diabetes, Oncology |
Oncology board of Novartis |
ETH Zürich |
| eSE010 |
Immunology, Human Antibodies |
Biotech Advisor |
IBMS Bellinzona |
| eSE011 |
Transcription Networks, Systems Biology |
Biotech Advisor |
UC Berkeley |
| eSE012 |
Immunology, Immunotherapy |
Pharmexa, Inc, Covagen, MVM Lifecience |
International Entrepreneur Fund |
| eSE013 |
Bioinformatics, Systems Biology |
Novartis, Glaxo Smith Kline |
Swiss Institute of Bioinformatics |
| eSE014 |
Virology, Endocytosis |
3V Biosciences |
ETH Zürich |
| eSE015 |
Cell Biology, Glycosylation |
Biotech Advisor |
University of Geneva |
| eSE016 |
Metabolomics |
Biotech advisor |
ETH Zürich |
| eSE017 |
Insulin signaling, Diabetes |
Biotech Advisor |
|
| eSE018 |
Clinical Oncology, Molecular Diagnostics |
Pharma Advisor |
Hirslanden Clinic Zürich |
| eSE019 |
Viruses, Membranes, Lipidomics |
Biotech Advisor |
EPFL |
| eSE020 |
Cancer, DNA Repair, Methylation |
Group Leader at Merck |
University of Zurich |
| eSE021 |
Chemistry, Combinatorial Chemistry, Drug Development |
|
Carlsberg Research Center |
| eSE022 |
Cancer, Cell biology, Genetics |
Founder of Start-up company |
MPI Dresden, Germany |
| eSE023 |
Stem Cells, Mouse Maintenance |
Biotech experience, responsible for the
Genome Modification Facility at Harvard |
Harvard University |
| eSE024 |
Mass Spectrometry |
Built-up Celera Proteomics |
ETH Zurich |
| eSE025 |
Epigenetics, Plant Science |
|
University of Zurich |
| eSE026 |
Pharmacology |
Hoffmann La Roche |
University of Zurich |
| eSE027 |
Neuroscience, Spinal Cord Injury |
Novartis |
University of Zurich |
| eSE028 |
Structural Biology, Rational Drug Design |
CIBA |
University of Zurich |
| eSE029 |
Neurodegeneration |
Start-up Company |
University of Zurich |
| eSE030 |
Infectious Diseases |
Consulting for pharmaceutical companies |
University of Basel |
| eSE031 |
Parasitology and Infectious Diseases |
Previously Board member of a biotech company |
The Walter and Eliza Hall |
| eSE032 |
Immunology, Oncology, Mouse Models |
Consulting for pharmaceutical and biotech companies |
University of Toronto |
| eSE033 |
Protein Folding |
|
MPI Munich |
| eSE034 |
Biotech, Platform Technologies |
Biotech, KTI |
FHNW, Basel |
| eSE035 |
Apoptosis cancer |
|
University of Kyoto |
| eSE036 |
Ageing Science |
Pharma |
University College London |
| eSE037 |
Neurosciences, Neurorepair |
Pharma |
University of Cambridge |
| eSE038 |
Bioinformatics, Systems Biology |
Biotech |
ETH Zurich |
| eSE039 |
Stem Cells |
Biotech |
Harvard University |
| eSE040 |
Stroke, Neurodegeneration, Clinical and Basic |
Pharma |
Lund University Hospital |
| eSE041 |
Radiology, Imaging |
Pharma, consultant for GE |
University Hospital Zurich |
| eSE042 |
Proteomics, Systems Biology |
Pharma |
University of Ottawa |
| eSE043 |
Cell Biology, Virology |
Biotech |
University of Zurich |
| eSE044 |
Computational Biology, Systems Biology |
|
ETH Zurich |
| eSE045 |
Proteomics, Systems Biology |
Biotech, Vice President Analystical Sciences |
TU Munich |
| eSE046 |
Proteomics, Systems Biology |
Biotech |
The Rockefeller University |
